What is Semaglutide?
Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1) hormone. It is engineered to be resistant to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), resulting in a significantly prolonged half-life compared to the natural hormone. This allows for once-weekly subcutaneous administration or once-daily oral formulation (in the case of Rybelsus®).
Its mechanism of action is multifaceted, directly targeting the pathophysiology of type 2 diabetes and obesity. Semaglutide binds to and activates GLP-1 receptors in several key organs:
1.Pancreas: It stimulates glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing glucagon release from alpha cells. This dual action effectively lowers blood glucose levels with a low risk of hypoglycemia when not combined with insulin or sulfonylureas.
2.Brain: It acts on appetite centers in the hypothalamus, promoting satiety and reducing hunger, which leads to a decreased caloric intake.
3.Stomach: It delays gastric emptying, which contributes to increased feelings of fullness and a slower, more controlled postprandial rise in blood glucose.
The Efficacy of Semaglutide
The efficacy of semaglutide is robustly supported by extensive clinical trial data, leading to its approval for specific indications.
1.Glycemic Control in Type 2 Diabetes: In numerous large-scale trials (such as the SUSTAIN program), semaglutide has demonstrated superior efficacy in reducing hemoglobin A1c (HbA1c) compared to other antidiabetic agents, including sitagliptin, empagliflozin, and even insulin glargine. Patients often achieve clinically significant reductions in HbA1c, frequently exceeding 1.5%.
2.Weight Management: The STEP clinical trial program established semaglutide as a powerful anti-obesity medication. At a higher dose (2.4 mg weekly) specifically approved for chronic weight management, participants achieved an average weight loss of 15-20% of their body weight over 68 weeks, when combined with lifestyle interventions. This level of efficacy surpasses that of previous anti-obesity pharmacotherapies.
3.Cardiovascular Benefits: Semaglutide has demonstrated significant cardiovascular (CV) benefits. The SUSTAIN 6 trial showed that, in patients with type 2 diabetes and established CV disease, semaglutide reduces the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction and non-fatal stroke.
Suitable Patient Population
The prescription of semaglutide must be tailored to specific, approved patient populations.
For Type 2 Diabetes: It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is often considered after metformin, but its potent efficacy and CV benefits may position it earlier in the treatment algorithm for high-risk patients.
For Chronic Weight Management: It is approved for adults with a body mass index (BMI) of ≥30 kg/m² (obesity), or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). It is intended for use alongside a reduced-calorie diet and increased physical activity.
How to get Semaglutide?
You can contact us directly:
Email:.sales8@bpandabio.com
WhatsApp: +86 151 7090 3910
Or click the picture
